

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Psychopharmacologic Drugs Advisory Committee (PDAC)***  
***June 4, 2024***

**DRAFT MEETING ROSTER**

---

---

**DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Joyce Frimpong, PharmD**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Walter S. Dunn, MD, PhD**

Assistant Clinical Professor  
Department of Psychiatry  
University of California Los Angeles  
Director, Mood Disorders Section  
Director, Interventional Psychiatry Service  
West Los Angeles Veterans Affairs (VA)  
Medical Center  
Los Angeles, California

**Jess G. Fiedorowicz, MD, PhD**

Head and Chief, Department of Mental Health  
The Ottawa Hospital  
Professor and Senior Research Chair in Adult  
Psychiatry, Department of Psychiatry  
University of Ottawa  
Ottawa, Ontario

**Satish Iyengar, PhD**

Chair and Professor of Statistics  
Department of Statistics  
University of Pittsburgh  
Pittsburgh, Pennsylvania

**Rajesh Narendran, MD**

*(Chairperson)*  
Attending Psychiatrist  
resolve Crisis Services  
UPMC Western Psychiatric Hospital  
Professor in Radiology and Psychiatry  
University of Pittsburgh School of Medicine  
Psychiatric Molecular Imaging Program  
Pittsburgh, Pennsylvania

**Kim O. Witzak**

*(Consumer Representative)*  
Co-Founder, Executive Director  
Woodymatters  
Minneapolis, Minnesota

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Psychopharmacologic Drugs Advisory Committee (PDAC)***  
***June 4, 2024***

**DRAFT MEETING ROSTER (cont.)**

---

---

**PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)**

**Carla M. Canuso, MD**

*(Industry Representative)*

Vice President

Head of Neuropsychiatry Clinical Development

Janssen Research and Development, LLC

Titusville, New Jersey

**TEMPORARY MEMBERS (Voting)**

**Maryann Amirshahi, PharmD, MD, MPH,**  
**PhD**

Professor of Emergency Medicine

Georgetown University School of Medicine

Co-Medical Director, National Capital Poison  
Center

Washington, District of Columbia

**Melissa Decker Barone, PsyD**

VA Maryland Health Care System (VAMHCS)

Trauma Recovery Program Staff Psychologist

Adjunct Assistant Professor in the Department of

Psychiatry University of Maryland School of  
Medicine

VAMHCS

Baltimore, Maryland

**John B. Hertig, PharmD, MS, CPPS,**  
**FASHP, FFIP**

Associate Professor, Department of Pharmacy  
Practice

Director, Pharmaceutical Fellowship Program

Butler University College of Pharmacy and

Health Sciences

Indianapolis, Indiana

**Paul E. Holtzheimer, MD**

Deputy Director for Research

Director, VA Posttraumatic Stress Disorder  
(PTSD) Brain Bank

National Center for PTSD

Professor, Psychiatry and Surgery

Geisel School of Medicine at Dartmouth

White River Junction, Vermont

**Elizabeth Joniak-Grant, PhD**

*(Patient Representative)*

Sociologist, Qualitative Research Consultant

Injury Prevention Research Center

University of North Carolina, Chapel Hill

Chapel Hill, North Carolina

**Mary E. Rebo, PharmD, MBA, CPPS**

Executive Director, Pharmacy Quality and  
Medication Safety

National Pharmacy Services

Kaiser Permanente

Los Angeles, California

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Psychopharmacologic Drugs Advisory Committee (PDAC)***  
***June 4, 2024***

**DRAFT MEETING ROSTER (cont.)**

---

---

**FDA PARTICIPANTS (Non-Voting)**

**Peter Stein, MD**

Director  
Office of New Drugs (OND)  
CDER FDA

**Teresa Buracchio, MD**

Director  
Office of Neuroscience (ON)  
OND, CDER, FDA

**Tiffany R. Farchione, MD**

Director  
Division of Psychiatry (DP)  
ON, OND, CDER, FDA

**Jean Kim, MD**

Cross Discipline Team Lead  
DP, ON, OND, CDER, FDA

**Peiling Yang, PhD**

Supervisory Mathematical Statistician  
Division of Biometrics I (DBI)  
Office of Biostatistics (OB)  
Office of Translational Sciences (OTS)  
CDER, FDA

**Cynthia LaCivita, PharmD**

Director  
Division of Risk Management (DRM)  
Office of Medication and Error Prevention and  
Risk Management (OMEPRM)  
Office of Surveillance and Epidemiology (OSE)  
CDER, FDA